Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The user experienced positive hair regrowth after 6 months of treatment, using topical minoxidil and finasteride, with no significant side effects. They also improved their diet and exercise routine, and are considering dermarolling if progress stalls.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A user shared their 6-month hair loss treatment progress, which included 3200 FUE grafts, oral finasteride and minoxidil, keto shampoo, and biotin. The user also mentioned micro needling their temples for further growth and plans to observe the effects of finasteride and minoxidil over the next 6-12 months.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Significant hair regrowth was achieved over six years using Minoxidil, Finasteride, and daily 0.25mm dermarolling. Finasteride had the most significant impact, with no reported side effects.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The user is very satisfied with their hair transplant results after six months, using finasteride, minoxidil, and ketoconazole shampoo. They praise Dr. Anuj and consider future touch-ups for a small untouched crown area.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The 6 month progress of a 40 year old user using topical Finasteride and Minoxidil and weekly Microneedling to treat hair loss, with other users offering advice and asking questions.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation discusses hair loss and the use of Dutasteride for treatment. One participant strongly supports the use of Dutasteride.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

A user experienced significant hair improvement using oral finasteride for six months, adding microneedling and switching to non-sulfate shampoo. They managed side effects by working out and noticed no negative impact on libido.

Significant hair regrowth was achieved over six months using minoxidil, finasteride, microneedling, biotin and collagen shampoo, and MSM powder. The user feels more confident and may consider a hair transplant if necessary.

A 59-year-old man with significant hair loss has seen some improvement, including reversal of Retrograde Alopecia and darkening of hair, after switching to RU58841 and a new minoxidil base solution with additional ingredients. He also changed from a derma roller to a derma stamp for application.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.

A user shared their 6-month progress with hair loss treatment, showing significant improvement. They used 1mg Propecia daily, Rogaine foam (5% minoxidil) after morning showers, and CG210 spray before bedtime.

A user shared their 6-month hair loss progress using topical minoxidil, oral finasteride, and microneedling, reporting positive results despite recent shedding. They also mentioned using rosemary oil and a special head lotion for dandruff.